Jon StojanNuminus is a leading player in the emerging field of psychedelic therapy. This article delves into their groundbreaking work and collaboration with MAPS (Multidisciplinary Association for Psychedelic Studies) to advance MDMA-assisted therapy in North America.
In the quest for a life enriched with love, connection, and profound meaning, an increasing number of individuals are turning to the transformative realm of psychedelic treatment—a gateway to profound journeys within consciousness. At the forefront of this groundbreaking field stands MDMA, the chemical substance affectionately known by its street names “molly” or “ecstasy,” captivating the attention of researchers, therapists, and those on a quest for enhanced well-being.
When administered within a controlled and therapeutic setting, MDMA becomes a potent tool for unlocking deep-seated emotions, fostering self-discovery, and enriching interpersonal relationships. This unique chemical ally serves as a portal to profound experiences, grounded in its ability to induce a heightened state of emotional openness and introspection.
Leading the charge in the emerging landscape of psychedelic therapy and the utilization of MDMA as a healing tool is Numinus. Founded by Payton Nyquvest, this mental health care company has forged a strategic alliance with MAPS (Multidisciplinary Association for Psychedelic Studies) to propel the evolution of MDMA-assisted therapy in North America.
“We see Numinus as playing a critical role in ensuring that therapists have the option to volunteer for experiential training to become fully trained on the latest medicines and their therapeutic methodologies,” Rick Doblin, Ph.D., the Founder and President of MAPS, says.
Numinus is not just a company; it’s a venture born out of necessity, driven by Nyquvest’s personal experience with severe chronic pain. Faced with diminishing options and frequent hospitalizations, Nyquvest turned to psychedelics as a last-ditch effort to alleviate his suffering. The transformative power of psychedelics became abundantly clear during a pivotal experience, inspiring him to establish Numinus.
Reflecting on his journey, Nyquvest recounts, “When I came back from that experience, and this was before any psychedelic industry was established, I was fortunate enough to meet Rick Doblin, Founder of MAPS. I was talking to him, and he said to me, ‘There’s all this research happening surrounding psychedelic therapy, but nobody’s building the infrastructure to actually offer it and hold it once it’s approved.’ So that’s really where I focused my efforts, not just on providing the experience but providing a container that can hold these experiences with all of the right supportive practices.”
Operating with a holistic approach, Nyquvest recognizes that the efficacy of psychedelic interventions extends beyond the substances themselves. Anchored in the belief that preparation, integration, and a supportive environment are essential, Numinus aims to maximize the therapeutic potential of psychedelics.
“That includes working with a therapist for a period of time, educating yourself on the process and what the potential can be in an MDMA therapy session so that when you do move into that, you’re really getting the most out of it,” he says.
Under Nyquvest’s leadership, Numinus has emerged as a pivotal player in providing access to transformative experiences for others. Today, their clinics in both Canada and the United States treat over 100,000 clients every year.
In addition to providing individualized psychedelic experiences, Numinus has actively contributed to changing the legal landscape for psychedelic therapies in Canada. By participating in altering the Special Access drug program, the company has facilitated legal access to various psychedelic therapies, including MDMA-assisted therapy and psilocybin-assisted therapy.
“Psychedelics were previously not allowed to be applied for in a Canadian clinic, but we were fortunate enough to help support regulation change a few years ago,” Nyquvest adds. Additionally, in a landmark achievement in 2022, Numinus successfully completed its inaugural MDMA administration in a PTSD trial sponsored by MAPS, marking a significant milestone in the exploration of MDMA’s therapeutic potential.
MAPS, a venerable organization with a legacy spanning nearly four decades, has conducted pivotal clinical trials with MDMA, establishing itself as an expert in psychedelic research. The collaboration between Numinus and MAPS symbolizes a joint commitment to advancing clinical trials, pushing the boundaries of research, and shaping the evolving landscape of psychedelic therapy.
As the legal and societal acceptance of these therapies grows, Numinus stands as a beacon in providing a comprehensive and supportive framework for individuals seeking healing through psychedelics.
“MAPS anticipates that in the next couple of years, we’ll be needing 30 to 50,000 trained therapists to administer MDMA to treat PTSD. Right now we only have a handful, and there’s a lot to do to ensure our practitioners can start up a practice and support clients,” Nyquvest shares.
As MDMA-assisted therapy continues to gain recognition and acceptance, its role as a tool for unlocking deep emotions, promoting self-discovery, and enhancing interpersonal relationships is becoming increasingly evident.
The ongoing research and collaborations, such as that between Numinus and MAPS, contribute to the understanding and responsible utilization of MDMA in the quest for mental health and profound personal transformation.
To learn more about Numinus and keep up with their work in the realm of psychedelic treatments, be sure to visit their website today.